Drug Development

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

Articles

BioPharm highlights the monoclonal antibodies that may gain United States regulatory approval in 2016.

mAbs to Watch in 2016

Appropriate use of sound science applied at critical junctures will improve efficiency in the high-wire act of drug development.

Phase-Appropriate Formulation and Process Design

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Liquid formulations in hard-shell capsules or softgels are becoming a popular option for HPAPIs because of advantages such as improved safety and lower risk of potential exposure and product cross contamination.

Liquid Encapsulation for HPAPIs

The DF30Plus, a new version of Aptar Pharma’s aerosol metering valve for pressurized metered dose inhalers (pMDIs), incorporates an elastomeric cyclic-olefin-copolymer (COC) neck gasket.

Metering Valve Incorporates COC Neck Gasket

Agnes Shanley is senior editor of Pharmaceutical Technology.

Synthetic biology promises to drive tomorrow’s therapies, while continuous processing is already being used in some new drugs.

Oncology and Rare Diseases Lead in Innovation

Boehringer Ingelheim announced it will establish a new biopharmaceutical production facility in Vienna.

Boehringer Ingelheim to Establish Biopharmaceutical Production Facility in Vienna

Recipharm has signed an agreement with Sweddish pharmaceutical company LIDDS for the production scale up and manufacture of LIDDS’ Liproca depot for the treatment of prostate cancer.

Recipharm Signs Agreement to Manufacture Liproca Depot

The aim of the collaboration is to advance the use of Cellectar’s phospholipid drug conjugate platform for targeted delivery of a selection of Pierre Fabre’s cytotoxics.

Cellectar Biosciences and Pierre Fabre Form Oncology Pact

Synpromics announced collaborations with Avalanche Biotechnologies and Applied Genetic Technologies Corporation to use synthetic promoters to develop gene therapies, including adeno-associated virus technology for treating eye diseases.

Synpromics Collaborates on Gene Therapies

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Collaboration between users and suppliers to increase understanding, clearly define user requirements, and mitigate risk is facilitating acceptance by industry and regulators.

Formulation and Drug Delivery